Inside The Kamen Brain Tumor Gala

200 donors joined Dr. Mazen Kamen to hear of advancements in pediatric brain tumor research. "Brain cancer has surpassed leukemia as the number one cause of cancer deaths among children”, shared Dr. Kamen, “It’s a devastating disease that affects both children and adults across racial and socioeconomic divides. More than 28,000 children are living with a brain tumor in the United States and an estimated 4,000 new cases of childhood brain tumors are expected to be diagnosed this year. "

Dr. Kamen

Dr. Kamen

The evening's host, CNBC senior editor Barbara Booth, greeted guests saying, "It's a very special night and I'm beyond honored to be here. As an investigative reporter for CNBC I have been reporting on cutting edge treatments for illnesses and injuries along with meeting the amazing doctors behind these revolutionary breakthroughs. Every one of you in this room brings this foundation to life and I thank you for that." CNBC's Sharon Epperson added, "Right now for children ages 0 to 14, glioma central nervous system tumors are the leading cause of cancer-related deaths, discovering new treatments for these tumors will take much funding and research. It's going to take a village for this, and we have one right here. I applaud this Foundation and all of you here tonight for making this important commitment to find a cure." Keynote speaker Dr. Herbert Pardes reinforced the need for research, "We’re seeking a quality survival. A cure, of course, it's what we want.  Research funded by this foundation is helping us slowly move in that direction." 

The Athenians

The Athenians

The evening was enlivened by a stellar performance by The Athenians, an ensemble of exceptional professional soloists from the Metropolitan Opera and other leading opera companies who performed classic arias while mixing among the dinner tables.  

Have a listing you think should be featured contact us or email at Jeremy@offthemrkt.com to tell us more! Follow Off The MRKT on Twitter and Instagram, and like us on Facebook.